# SCNI (Scinai Immunotherapeutics Ltd.) - SEC EDGAR Financial Statements

> Scinai Immunotherapeutics Ltd. reported $1.31M in revenue and a net loss of $8.31M for the fiscal year ended December 31, 2025 (up 99.2% year over year), with a -202.3% gross margin and a -575.3% operating margin.

- Canonical: https://convexityos.com/fundamentals/SCNI
- Markdown: https://convexityos.com/fundamentals/SCNI.md
- SEC CIK: 0001611747
- Reporting currency: USD
- Latest filing period: December 31, 2025
- Last synced: Nov 21, 2026, 05:15 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001611747&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | $1.31M | +99.2% YoY |
| Operating Income | FY 2025 | -$7.54M | -575.3% margin |
| Net Income | FY 2025 | -$8.31M | -633.6% net margin |
| Diluted EPS | FY 2025 | -- | Split-adjusted |
| Free Cash Flow | FY 2025 | -$6.05M | -461.9% FCF margin |
| Cash & ST Investments | Dec 31, 2025 | $1.66M | Total debt: $1.96M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| **Revenue** | $1.31M | $658K | -- | -- | -- |
| Cost of Revenue | $3.96M | $1.24M | -- | -- | -- |
| **Gross Profit** | -$2.65M | -$580K | -- | -- | -- |
| Research & Development | $2.37M | $5.53M | $5.21M | $5.76M | $3.25M |
| Selling, General & Admin | $2.52M | $2.53M | $4.50M | $5.30M | $7.62M |
| Total Operating Expenses | $4.89M | $8.06M | $9.71M | $11.06M | $10.86M |
| **Operating Income** | -$7.54M | -$8.64M | -$9.71M | -$11.06M | -$10.86M |
| **EBITDA** | -$6.12M | -$6.99M | -$9.19M | -$10.50M | -$10.39M |
| Interest Expense | -- | -- | $343K | $351K | $336K |
| **Net Income** | -$8.31M | $4.80M | -$6.50M | -$5.80M | -$8.21M |
| Basic EPS | -- | -- | $0.00 | $0.01 | -$0.02 |
| **Diluted EPS** | -- | -- | $0.00 | $0.01 | -$0.02 |
| Basic Shares Outstanding | 9.34B | 3.23B | 1.56B | 754.1M | 564.6M |
| Diluted Shares Outstanding | 9.34B | 3.23B | 1.56B | 754.1M | 564.6M |

### Income Statement (Quarterly)

| Line Item | Mar 2023 | Mar 2022 |
| --- | --- | --- |
| Research & Development | $2.00M | $1.16M |
| **Operating Income** | -$3.19M | -$2.62M |
| **EBITDA** | -$3.05M | -$2.48M |
| **Net Income** | -$3.52M | -$2.48M |
| Basic EPS | -$0.00 | -$0.00 |
| **Diluted EPS** | -$0.00 | -$0.00 |
| Basic Shares Outstanding | 1.30B | 744.7M |
| Diluted Shares Outstanding | 1.30B | 744.7M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $1.66M | $1.96M | $4.87M | $14.07M | $17.37M |
| **Cash & Short-Term Investments** | $1.66M | $1.96M | $4.87M | $14.07M | $17.37M |
| Accounts Receivable, Net | $73K | $83K | -- | -- | -- |
| Other Current Assets | -- | -- | $437K | $155K | -- |
| **Total Current Assets** | $2.05M | $2.39M | $5.45M | $14.37M | $17.84M |
| Property, Plant & Equipment, Net | $7.79M | $9.19M | $10.82M | $11.24M | $12.39M |
| **Total Non-Current Assets** | $9.57M | $11.06M | $12.03M | $12.70M | $14.19M |
| **Total Assets** | $11.63M | $13.45M | $17.47M | $27.07M | $32.04M |
| Accounts Payable | $407K | $376K | $535K | $716K | $999K |
| Short-Term Debt | -- | -- | -- | $382K | $375K |
| Deferred Revenue (Current) | $90K | $225K | -- | -- | -- |
| **Total Current Liabilities** | $1.58M | $1.81M | $1.78M | $2.34M | $2.44M |
| **Total Non-Current Liabilities** | $1.94M | $1.67M | $20.26M | $26.49M | $28.61M |
| **Total Liabilities** | $3.52M | $3.47M | $22.04M | $28.83M | $31.05M |
| **Total Debt (incl. Leases)** | $1.96M | $1.83M | $1.19M | $764K | $1.82M |
| Retained Earnings | -$125.8M | -$117.5M | -$122.3M | -$115.8M | -$110.0M |
| Accumulated Other Comp. Income | -$1.74M | -$1.74M | -$1.74M | -$2.01M | -$2.06M |
| **Total Stockholders' Equity** | $8.10M | $9.98M | -$4.57M | -$1.76M | $982K |
| Total Equity | $8.10M | $9.98M | -$4.57M | -$1.76M | $982K |

### Balance Sheet (Quarterly)

| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2022 | Dec 2021 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $1.66M | $1.96M | $4.87M | $10.80M | $14.07M | $17.37M |
| **Cash & Short-Term Investments** | $1.66M | $1.96M | $4.87M | $10.80M | $14.07M | $17.37M |
| Accounts Receivable, Net | $73K | $83K | -- | -- | -- | -- |
| Other Current Assets | -- | -- | $437K | -- | $155K | -- |
| **Total Current Assets** | $2.05M | $2.39M | $5.45M | $11.04M | $14.37M | $17.84M |
| Property, Plant & Equipment, Net | $7.79M | $9.19M | $10.82M | $10.82M | $11.24M | $12.39M |
| **Total Non-Current Assets** | $9.57M | $11.06M | $12.03M | $12.25M | $12.70M | $14.19M |
| **Total Assets** | $11.63M | $13.45M | $17.47M | $23.29M | $27.07M | $32.04M |
| Accounts Payable | $407K | $376K | $535K | $1.31M | $716K | $999K |
| Short-Term Debt | -- | -- | -- | -- | $382K | $375K |
| Deferred Revenue (Current) | $90K | $225K | -- | -- | -- | -- |
| **Total Current Liabilities** | $1.58M | $1.81M | $1.78M | $2.58M | $2.34M | $2.44M |
| **Total Non-Current Liabilities** | $1.94M | $1.67M | $20.26M | $25.52M | $26.49M | $28.61M |
| **Total Liabilities** | $3.52M | $3.47M | $22.04M | $28.10M | $28.83M | $31.05M |
| **Total Debt (incl. Leases)** | $1.96M | $1.83M | $1.19M | $420K | $764K | $1.82M |
| Retained Earnings | -$125.8M | -$117.5M | -$122.3M | -$119.3M | -$115.8M | -$110.0M |
| Accumulated Other Comp. Income | -$1.74M | -$1.74M | -$1.74M | -$1.89M | -$2.01M | -$2.06M |
| **Total Stockholders' Equity** | $8.10M | $9.98M | -$4.57M | -$4.81M | -$1.76M | $982K |
| Total Equity | $8.10M | $9.98M | -$4.57M | -$4.81M | -$1.76M | $982K |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Net Income | -$8.31M | $4.80M | -$6.50M | -$5.80M | -$8.21M |
| Depreciation & Amortization | $1.42M | $1.65M | $514K | $562K | $471K |
| Stock-Based Compensation | $303K | $682K | $1.14M | $1.60M | $2.76M |
| Change in Receivables | $10K | -$83K | -- | -- | -- |
| Change in Payables | $31K | -$156K | -$150K | -$175K | $3.0K |
| **Operating Cash Flow** | -$6.03M | -$6.33M | -$9.38M | -$7.26M | -$7.43M |
| Capital Expenditure | -$24K | -$12K | -$637K | -$836K | -$139K |
| **Free Cash Flow** | -$6.05M | -$6.35M | -$10.02M | -$8.10M | -$7.57M |
| **Investing Cash Flow** | -$24K | -$12K | -$637K | -$836K | -$139K |
| Common Stock Issued | -- | $2.00M | $139K | $932K | $21.43M |
| **Financing Cash Flow** | $5.77M | $3.44M | $1.09M | $6.78M | $21.43M |
| **Net Change in Cash** | -$284K | -$2.92M | -$9.21M | -$3.30M | $14.44M |

### Cash Flow Statement (Quarterly)

| Line Item | Mar 2023 | Mar 2022 |
| --- | --- | --- |
| Net Income | -$3.52M | -$2.48M |
| Depreciation & Amortization | $138K | $134K |
| Stock-Based Compensation | $252K | $485K |
| Change in Payables | $629K | $311K |
| **Operating Cash Flow** | -$3.06M | -$1.10M |
| Capital Expenditure | -$6.0K | -$521K |
| **Free Cash Flow** | -$3.06M | -$1.63M |
| **Investing Cash Flow** | -$6.0K | -$521K |
| **Net Change in Cash** | -$3.29M | -$1.99M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| **Gross Margin** | -202.3% | -88.1% | -- | -- | -- |
| **Operating Margin** | -575.3% | -1312.8% | -- | -- | -- |
| **Net Profit Margin** | -633.6% | 728.9% | -- | -- | -- |
| Return on Equity (ROE) | -102.5% | 48.1% | -- | -- | -835.6% |
| Return on Assets (ROA) | -71.5% | 35.7% | -37.2% | -21.4% | -25.6% |
| Current Ratio | 1.30x | 1.32x | 3.06x | 6.15x | 7.30x |
| Quick Ratio | 1.09x | 1.13x | 2.74x | 6.02x | 7.11x |
| Debt to Equity | 0.24x | 0.18x | -- | -- | 1.85x |
| **Revenue Growth (YoY)** | +99.2% | -- | -- | -- | -- |
| **Net Income Growth (YoY)** | -273.2% | -- | -- | -- | -- |
| EPS Growth (YoY) | -- | -- | -60.0% | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Mar 2023 | Mar 2022 |
| --- | --- | --- |
| Current Ratio | 4.28x | -- |
| Quick Ratio | 4.19x | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
